|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Bone metastases as assessed with <sup>68</sup>Ga-PSMA-11 PET/CT are prevalent even in patients with low serum PSA levels.
|
31541035 |
2020 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we reported that miR‑505‑3p was significantly downregulated in bone metastatic PCa tissues compared with that in non‑bone metastatic PCa tissues, but there was no significant difference in miR‑505‑3p expression between PCa and adjacent normal tissues. miR‑505‑3p expression was inversely associated with serum PSA levels, Gleason grade, N and M classification, and short bone metastasis‑free survival in PCa patients, but had no effect on overall survival in PCa patients.
|
30365141 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
AR-V7 was associated with indicators of advanced and high-volume disease at baseline, including higher prostate-specific antigen (PSA) level (p < 0.001), more bone metastases (p < 0.001), docetaxel for hormone-sensitive disease (p < 0.001), prior first-generation androgen deprivation therapy (p < 0.001), and shorter time from diagnosis to enrollment (p < 0.001).
|
31542304 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PSA levels, along with other parameters, may determine the risk of having BM.
|
30843003 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We try to correlate the PSA value with bone metastases through bone scan in the Indian population.
|
30900618 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bisphosphonates had been widely used in the treatment of metastatic prostate bone metastases given their demonstrated benefit with a delay of skeletal-related events (SREs) but without prostate-specific antigen (PSA) response or overall survival benefit.
|
30730775 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariable logistic regression analysis starting with the following clinical risk factors (PSA level, Gleason Score and age) and imaging biomarkers were applied to develop diagnostic model for BM in PCa.
|
30917943 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In multivariate analyses, PFS was significantly associated with existing bone metastasis at diagnosis (P = 0.005) and OS with PSA > 100 ng/ml (P = 0.007), hemoglobin < 12 g/dl (P = 0.030), and low initial CBZ dose (P = 0.030).
|
30770773 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the role of <sup>68</sup>Gallium prostate-specific membrane antigen-positron emission tomography/computed tomography (<sup>68</sup>Ga-PSMA-11 PET/CT) derived quantitative volumetric tumor parameters in comparison with fully diagnostic conventional CT and serum-PSA levels for classification and evaluation of therapeutic response of bone metastases in patients with metastasized prostate cancer (PC).
|
31338731 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA relapse was observed in one patient (1.08%) in the low-risk group (pelvic lymph node involvement was detected) and in seven patients (6.5%) in the intermediate-risk group (three lymph node metastases, two lymph node and bone metastases, two PSA relapses).
|
31486267 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ten or more bone metastases (HR, 2.17; 95% CI, 1.72-2.74), undergoing radical prostatectomy (HR, 0.73; 95% CI, 0.61-0.89), shorter progression to CRPC (HR, 0.97; 95% CI, 0.94-0.99), older age (HR, 1.03; 95% CI, 1.02-1.04), higher prostate-specific antigen level at the time of diagnosis of metastasis (HR, 1.21; 95% CI, 1.14-1.28), bone pain (HR, 1.44; 95% CI, 1.23-1.70), and visceral metastasis (HR, 1.72; 95% CI, 1.23-2.39) were associated with an increased mortality risk.
|
31390061 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the very-low testosterone group, enzalutamide use (HR 3.07, 95% CI 1.36-6.94; P = 0.007), primary androgen deprivation therapy <12 months (HR 2.50, 95% CI 1.23-5.08; P = 0.011) and bone metastases (HR 2.60, 95% CI 1.20-5.64; P = 0.015) were significantly associated with PSA progression.
|
31103335 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis showed that age, marital status, PSA, biopsy Gleason score, T stage, and bone metastasis were independent risk factors for both OS and CSS.
|
31289983 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As for treatment, it is paramount to identify patients who fall into one of the six well defined "favorable" subset categories, namely extragonadal germ cell tumors, adenocarcinoma with isolated unilateral axillary lymph nodes in female patients, squamous cell carcinoma with neck lymph nodes, squamous cell carcinoma with inguinal lymph nodes, serous papillary peritoneal carcinomatosis in females and blastic bone metastasis in males with elevated PSA.
|
29203116 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The level of prostate-specific antigen (PSA) in the patient was elevated to 167.0 ng/ml, and multiple bone metastases were detected.
|
30250608 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA PET visualizes more bone metastases than low-dose CT. PSA plasma levels are significantly correlated with several <sup>68</sup>Ga-PSMA PET parameters.
|
29362859 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients were pair matched for age, PSA level, clinical stage, preoperative biopsy Gleason score and bone metastases.
|
28974120 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUprostate is correlated with Gleason score and PSA serum concentration and allows prediction of the occurrence of lymph node and bone metastases with moderate accuracy at primary staging.
|
29401151 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) nadir level, time to PSA nadir, time to castration-resistant prostate cancer (CRPC), progression-free survival and therapy response of bone metastases were compared between the groups.
|
30246213 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression of RANK was highest in tumour tissue from patients with bone metastases (p < 0.001) as compared to BPH or locally confined tumours, also shown in clinical subgroups distinguished by Gleason Score (< 7 or ≥ 7, p = 0.028) or PSA level (< 10 or ≥ 10 µg/l, p = 0.004).
|
29204705 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 12 of 15 patients (80.0%) with a PSA between 0.5 and < 2.0 ng/mL, suspicious lesions were detected (four local recurrences, nine lymph nodes, and four bone metastases).
|
29032394 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher YKL-40 and PSA levels were detected in patients with bone metastasis (p = 0.032; p = 0.010) and in those who were not pre-treated with radical prostatectomy (p = 0.011, p = 0.008).
|
29949801 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen was the single most important predictor of bone metastases (P < .001).
|
27645522 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low expression of miR-141-3p positively correlates with serum PSA levels, Gleason grade and bone metastasis status in PCa patients.
|
29202848 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In univariable analysis, older age, more remote year of mCRPC, nonblack race, greater number of bone metastasis, higher prostate-specific antigen (PSA) levels, shorter PSA doubling time, and faster PSA velocity at mCRPC diagnosis were significantly associated with shorter overall survival (all P < .05).
|
27692812 |
2017 |